Health ❯ Healthcare

Side Effects

Medication Risks Medication Side Effects Gastrointestinal Issues Adverse Reactions Common Side Effects Drug Safety Drug Interactions Vaccine Reactions Adverse Events Drug Side Effects

Novo Nordisk Says Wegovy Pill Tops Lilly’s Foundayo in New Cross-Trial Analysis

The rival claims highlight a market that will be decided by convenience, coverage and how patients tolerate the drugs in everyday use.

EMA Backs First Combined COVID-19 and Flu Vaccine for Over-50s in EU

EU Regulators Back First Combined COVID-19 and Flu mRNA Shot for Adults 50 and Over

EMA Backs First Combined COVID–Flu Vaccine for People 50 and Over

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

GLP‑1 Use Under Scrutiny After Study on Tolerability and Delhi OTC Sales

WHO-Backed Reviews Affirm GLP-1 Weight-Loss Gains as Clinicians Flag Safety and Nutrition Gaps

NHS Renews Warnings on PPIs, Sets OTC Pantoprazole Limits

UK Regulator Adds Rare Vision‑Loss Warning to Ozempic, Wegovy and Rybelsus

Honey Energy Supplement Recalled After FDA Finds Undeclared ED Drug

NHS Reminds Sertraline Users to Avoid Grapefruit

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

NHS Guidance on Beclometasone Inhalers Reiterated, Flagging Age Limits and Trace Alcohol in Some Brands

FDA Approves First Oral Weight-Loss GLP-1: Wegovy Pill to Launch in January

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

NHS Reiterates Beta‑Blocker Guidance, Warning They Are Not Suitable for Everyone

Laís Caldas’ Pregnancy Renews Warnings on Mounjaro’s Effect on Oral Contraceptives

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

EMA Panel Backs Conditional EU Approval for Anktiva in BCG-Unresponsive Bladder Cancer